Navigation Links
Valeant Pharmaceuticals to Syndicate Incremental Term Loans
Date:11/30/2011

MISSISSAUGA, Ontario, Nov. 30, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced plans to syndicate $350 million of incremental term loans under its existing senior secured credit facilities to partially fund its previously announced acquisition of iNova.  The incremental term loans will mature in April 2016 and are expected to have terms that are consistent with the Company's existing $1.725 billion Term Loan A facility. The incremental term loans are expected to close in December 2011, subject to market and other customary conditions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
2. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
3. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
4. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
5. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
6. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
7. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
8. Valeant Pharmaceuticals to Present at Industry Conferences
9. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
10. Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid
11. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Los innovadores de ... mundo, introduce catéteres para la intervención de extremidades ... compañía global especializada en el suministro de soluciones ... cartera incluyendo productos para tratar la enfermedad arterial ... son los dispositivos de primera entrada de la ...
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 2016 , ... Consumer access to organic foods and grower access to food ... whole grain cereals and other plant-based foods, will introduce the first consumer product (a ... processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal was made ...
(Date:5/25/2016)... GA (PRWEB) , ... May 25, 2016 , ... ... solutions builder, has announced that it will join America's leading engineers at the ... be held at the Georgia World Congress Center. , Engineers, speakers and ...
(Date:5/25/2016)... ... 25, 2016 , ... American Spine in Frederick, Maryland is ... surgeries in the Montgomery County, Howard County and Washington, D.C. areas, renowned spine ... American Spine every Monday. He will also perform surgeries in our Germantown surgical ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching a ... patented refillable hanging wipe dispenser. The campaign kick-off video is located via this link ... 25, 2016. The goal is to raise $1,000 per day for a total of ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the ... joined the company as Vice President of Sales. Cifolelli’s primary responsibilities include ... sales in the rapidly expanding field of organizational social engineering. , “We ...
Breaking Medicine News(10 mins):